AL

Atai Life Sciences

IPO

Innovating Mental Health Treatments

Founded 2018 · $400.0M raised

Founded
2018
Business Model
B2B2C
Total Funding
$400.0M
Last Round
$50.0M Private EquityJul 2025
Rounds
5

About

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company formed in 2025 through the strategic combination of atai Life Sciences, founded in 2018, and Beckley Psytech, focused on developing rapid-acting, durable and convenient treatments for difficult-to-treat mental health conditions such as treatment-resistant depression. In July 2026, Eli Lilly agreed to acquire the company for approximately $6.75 per share in cash, an equity value of about $2.8 billion, pending closing.

Summary

Atai Life Sciences is a Biotech company, founded in 2018. It has raised $400.0M in total across 5 rounds, most recently a $50.0M Private Equity round in Jul 2025. Investors include Apeiron Investment Gro, Catalio Capital Management and Thiel Capital.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Private EquityPrivate EquityJul 2025
$50.0M

Sign up to see all 6 rounds

Series A through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Atai Life Sciences on Indexed.vc
<a href="https://indexed.vc/companies/atai-life-sciences"><img src="https://indexed.vc/api/badge/company/atai-life-sciences" alt="Atai Life Sciences on Indexed.vc" width="260" height="76" /></a>